Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

NCT02753686 · clinicaltrials.gov ↗

COMPLETED

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Interventions

DRUG: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
DRUG: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy

Sponsor

Novartis Pharmaceuticals